IP Library › Granted Patent US 8,466,163
Granted Patent B2
US 8,466,163 · App. 12/448,146 · Granted Jun 18, 2013

Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization

Inventors: Bernard Luke Flynn (Vermont, AU); Jason Hugh Chaplin (Thornbury, AU); Dharam Paul (Bellfield, AU); Damian Wojciech Grobelny (Watsonia North, AU); Brian Kelly (Ringwood East, AU)
Assignee: Bionomics Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,466,163
App. No.
12/448,146
Granted
Jun 18, 2013
Kind
B2
Abstract

The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which may possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.

Claims (31)

1. A compound of formula:

or a salt thereof, wherein;

X represents O;

Y represents a group of formula (i) or (ii);

wherein each one of R 1A , R 1B , R 1C , R 1D , and R 1E independently represents H, carboxyl, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphono, phosphorylamino, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted arylamino, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacylimino, optionally substituted oxyacyloxy, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or optionally substituted , thioacyloxy; or any of R 1A and R 1B , R 1B and R 1C , R 1C and R 1D , and R 1D and R 1E , together form an optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloalkenyl;

L represents C═O, O, S, SO, SO 2 , Se, SeO, SeO 2 , C═NZ′, or NR′ where Z′ is H, optionally substituted alkyl, optionally substituted aryl or optionally substituted amino, and where R′ is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted sulfonyl; and

Q represents H, CN, halogen, trialkylsilyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acylamino, optionally substituted aminoacylamino, OR″, SR″ or NR″R″, where each R″ independently represents, H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl and optionally substituted oxyacyl, or NR′″NR′″, where each R′″ independently represents H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl and optionally substituted heteroaryl; and

wherein Y and Q do not represent the same group.

2. A compound according to claim 1 or a salt thereof wherein Y represents a group of formula (i) where L is a carbonyl group (C═O) or a group of formula (ii).

3. A compound according to claim 1 or a salt thereof wherein R 1A and R 1E represents H.

4. A compound according to claim 3 or a salt thereof wherein furthermore R 1C represents H, halogen, or an alkoxy group and R 1D and R 1B independently represent an alkoxy group.

5. A compound according to claim 4 or a salt thereof wherein R 1D , R 1C and R 1B represent an alkoxy group.

6. A compound according to claim 5 or a salt thereof wherein R 1A and R 1E represent H and R 1D , R 1C and R 1B represent methoxy.

7. A compound according to formula (Ic) or a salt thereof:

wherein;

X represents O;

R 1F represents hydrogen, lower alkyl, lower alkylaryl, or optionally substituted phenyl;

R 1G represents hydrogen, lower alkyl, lower alkoxy, lower alkylaryl, or optionally substituted phenyl;

Y represents a group of formula (i)(b) or (ii)(a);

Q represents H, CN, halogen, trialkylsilyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acylamino, optionally substituted aminoacylamino, OR″, SR″ or NR″R″, where each R″ independently represents, H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl and optionally substituted oxyacyl, or NR′″NR′″, where each R′″ independently represents H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl and optionally substituted heteroaryl; and

wherein Y and Q do not represent the same group.

8. A compound according to claim 7 or a salt thereof wherein R 1F is hydrogen or lower alkyl and R 1G is hydrogen.

9. A compound according to claim 7 or a salt thereof wherein Q represents an optionally substituted phenyl group or an optionally substituted heteroaryl group.

10. A compound according to claim 7 or a salt thereof wherein Q represents indolyl, 1-methyl-indolyl, furanyl, pyrazolyl, or pyridinyl.

11. A compound selected from the group consisting of:

or a salt thereof.

12. A pharmaceutical composition comprising a compound according to claim 1 or a salt thereof together with a pharmaceutically acceptable additive.

13. A pharmaceutical composition comprising a compound according to claim 7 or a salt thereof together with a pharmaceutically acceptable additive.

14. A pharmaceutical composition comprising a compound according to claim 11 or a salt thereof together with a pharmaceutically acceptable additive.

15. A compound according to claim 1 or a salt thereof wherein Q represents an optionally substituted phenyl group or an optionally substituted heteroaryl group.

16. A compound according to claim 1 or a salt thereof wherein Q represents indolyl, 1-methyl-indolyl, furanyl, pyrazolyl, or pyridinyl.

Assignments (3)
REASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Apr 30, 2021
From: OXFORD FINANCE LLC
To: BIONOMICS, LTD
Reel/Frame 056106/0306 →
SECURITY INTEREST Recorded May 8, 2020
From: BIONOMICS LTD
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 052615/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2009
From: FLYNN, BERNARD LUKE; CHAPLIN, JASON HUGH; PAUL, DHARAM; GROBELNY, DAMIAN WOJCEICH; KELLY, BRIAN
To: BIONOMICS LIMITED
Reel/Frame 023690/0060 →
Continuity (2)
Provisional Application 60874125 · Dec 11, 2006
Related Publication 20100048591A1 · Feb 25, 2010